Drug Profile


Latest Information Update: 28 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Washington University
  • Developer Genentech
  • Class Antiparkinsonians; Nerve growth factors; Neuroprotectants
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

  • 06 Mar 2000 A study has been added to the Parkinson's Disease pharmacodynamics section
  • 24 Feb 1997 A study has been added to the Nervous System Disorders pharmacodynamics section
  • 29 Jan 1997 Preclinical development for Amyotrophic lateral sclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top